Target trial emulation of 205 patients with acute heart failure (LVEF ≤45%): starting vericiguat at discharge was associated with fewer 180-day HF rehospitalisations (16.3% vs 34.2%; HR 0.43); worsening HF events not significantly lower (HR 0.64, P=0.13).
RCTn = 205
Chen et al. Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study